dupilumab
regeneron,sanofi
['dupixent', 'dupilumab', '$regn']
$regn 2022-09-08 11:29 et dupixent (dupilumab) late-breaking phase 3 data at the eadv 2022 congress showed significant improvements in signs and symptoms of prurigo nodularis 
https://t.co/kGqHq6diS7